Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder

Trial Profile

A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Bipolar I disorders
  • Focus Adverse reactions; Registrational
  • Acronyms ATLAS
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 09 Oct 2018 Results assessing functional recovery and symptomatic remission after maintenance treatment with aripiprazole once-monthly in patients with bipolar I disorder, presented at the 31st Annual Congress of the European College of Neuropsychopharmacology
    • 04 May 2017 Status changed from recruiting to completed.
    • 08 Oct 2015 Planned number of patients changed from 1000 to 755 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top